Q4 2025 Altimmune Inc Earnings Call Transcript
Key Points
- Altimmune Inc (ALT) has received FDA Breakthrough Therapy designation for pemvidutide in MASH, indicating its potential for substantial improvement over existing therapies.
- The company has completed a $75 million capital raise, strengthening its financial position to support the initiation of Phase 3 trials.
- Pemvidutide has shown promising results in Phase 2 trials, with significant MASH resolution and antifibrotic activity at 48 weeks.
- The dual mechanism of pemvidutide, combining glucagon and GLP-1 agonism, offers a unique approach to addressing both hepatic and metabolic drivers of liver diseases.
- Altimmune Inc (ALT) has aligned with the FDA on the design of its pivotal Phase 3 study, which will enroll approximately 1,800 patients globally.
- The company faces significant competition in the MASH market, with other therapies also targeting similar patient populations.
- There are concerns about the tolerability and adherence to current and potential future therapies, which pemvidutide aims to address.
- The regulatory pathway for using noninvasive tests (NITs) as primary endpoints is still uncertain, as the FDA considers it premature.
- Altimmune Inc (ALT) anticipates increased cash usage as it approaches the launch of the MASH Phase 3 trial, necessitating further financial planning.
- The company is still finalizing protocol details for the Phase 3 trial, including biopsy procedures and patient enrollment strategies.
Good morning, ladies and gentlemen, and welcome to the Altimmune year-end 2025 financial results conference call. (Operator Instructions). As a reminder, this call is being recorded.
I'll now introduce your host for today's conference call, Lee Roth, President of Burns McClellan, Investor Relations Adviser to Altimmune. Lee, you may begin.
Thanks, Gigi, and good morning, everyone. Thank you for joining us for Altimmune's Fourth Quarter 2020 Financial Results and Business Update Conference Call. On today's call, you'll hear from Jerry Durso, our Chief Executive Officer; Dr. Christophe Arbet-Engels, Chief Medical Officer; Linda Richardson, Chief Commercial Officer; and Greg Weaver, Chief Financial Officer.
Following management's prepared remarks, we'll open the line for the Q&A session. Our fourth quarter and full year 2025, earnings release was issued this morning and can be found on the Investor Relations section of the Altimmune website.
Before we begin, I'd like to remind
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
